The impact of COVID-19 epidemic on the control of important parasitic diseases

doi:10.12140/j.issn.1000-7423.2021.03.011

Abstract

Abstract:

The spread of COVID-19 has increased the risk of contact transmission between people, and imposes challenges and opportunities for the prevention and control of important parasitic diseases. There may be risks of COVID-19 infection during the implementation of the virus control, including in field investigation and intervention, contacting with fecal samples, or with asymptomatic infected people. Therefore, corresponding prevention and control measures should be taken before and during field investigation, and in sample transportation and detection to prevent the risks effectively. In this paper, the risks and corresponding countermeasures in the above processes are discussed in detail, and the opportunities that COVID-19 brought to the disease control system are also analyzed.

Key words: COVID-19, Important parasitic diseases, Transmission risk, Control and prevention

CLC Number:

R532.21

ZHU Hui-hui, ZHU Ting-jun, CHEN Ying-dan, DENG Zhuo-hui, XU Jing, ZHOU Chang-hai, QIAN Men-bao, QIN Zhi-qiang, HUANG Ji-lei, LV Chao, ZHANG Mi-zhen, LI Shi-zhu. The impact of COVID-19 epidemic on the control of important parasitic diseases[J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2021, 39(3): 365-369.

References 30

[1]	Epidemiololgy Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China[J]. Chin J Epidemiol, 2020,41(2):145-151. (in Chinese)
	( 中国疾病预防控制中心新型冠状病毒肺炎应急响应机制流行病学组. 新型冠状病毒肺炎流行病学特征分析[J]. 中华流行病学杂志, 2020,41(2):145-151.)
[2]	WHO. Coronavirus disease(COVID-19) pandemic[EB/OL].(2021-6-4) [2021-6-4]. https://www.who.int/energencies/diseases/novel-coronavirus-2019.
[3]	National Health Commission of the People’s republic of China. The latest situation of COVID-19 up to 24 hours, 2nd, June [EB/OL]. (2021-6-4) [2021-6-4]. (in Chinese)
	( 国家卫生健康委员会. 截止6月2日24时新型冠状病毒肺炎疫情最新情况 [EB/OL]. (2021-6-4) [2021-6-4]. http://www.nhc.gov.cn/xcs/yqfkdt/202106/d0052d72bf1b433784dfa76bf1cad3db.shtml
[4]	Ministry of Finance, National Commission of Health and Family Planning. Notice on the budget target of 2016 public health service subsidy in advance, caishe[2015] No. 217. [2015-10-21]. http://sbs.mof.gov.cn/zxzyzf/ggwsfwbzzj/201801/t20180119_2798117.htm.
	( 财政部、卫生计生委. 关于提前下达2016年公共卫生服务补助资金预算指标的通知, 财社 [2015] 217号. [2015-10-21]. http://sbs.mof.gov.cn/zxzyzf/ggwsfwbzzj/201801/t20180119_2798117.htm
[5]	General Office of the National Health Commission. Notice on strengthening the management of key parasitic diseases prevention and control projects in local areas under the central transfer payment, The letter of national office for disease control and prevention [2020] No. 386. [2020-05-15].(in Chinese)
	( 国家卫生健康委员会办公厅. 关于加强中央转移支付地方重点寄生虫病防治项目管理工作的通知, 国卫疾控办函[2020]386号.[2020-05-15].)
[6]	Chinese Center for Disease Control and Prevention. Notice on the issuance of the work guidance plan for the prevention and control of soil-transmitted helminthasis and food-borne parasitic diseases. China CDC [2019] No. 100. [2019-10-09].(in Chinese)
	( 中国疾病预防控制中心. 关于印发土源性食源性寄生虫病防治项目工作指导方案的通知, 中疾控传防发[2019]100号.[2019-10-09].)
[7]	Chinese Center for Disease Control and Prevention. Notice on the issuance of the national schistosomiasis surveillance program (2014 edition), China CDC [2014] No. 420. [2014-11-13]. (in Chinese)
	( 中国疾病预防控制中心. 关于印发全国血吸虫病监测方案(2014年版)的通知,中疾控传防发 [2014] 420号. [2014-11-13].)
[8]	Li HZ. Analysis on the national surveillance program for schistosomiasis (2014)[J]. J Trop Dis Parasitol, 2015,13(1):1-3. (in Chinese)
	( 李华忠. 全国血吸虫病监测方案(2014年版)解析[J]. 热带病与寄生虫学, 2015,13(1):1-3.)
[9]	Xu J, Yang K, Li SZ, et al. Surveillance system after transmission control of schistosomiasis in P.R. China[J]. Chin J Schisto Control, 2014,26(1):1-5. (in Chinese)
	( 许静, 杨坤, 李石柱, 等. 我国血吸虫病传播控制后的监测体系[J]. 中国血吸虫病防治杂志, 2014,26(1):1-5.)
[10]	Liu X, Na RS, Bi ZQ. Challenges to prevent and control the outbreak of COVID-19[J]. Chin J Epidemiol, 2020,41(7):994-997. (in Chinese)
	( 刘霞, 娜日莎, 毕振强. 新型冠状病毒肺炎疫情防控所面临的挑战[J]. 中华流行病学杂志, 2020,41(7):994-997.)
[11]	Kampf G, Todt D, Pfaender S, et al. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents[J]. J Hosp Infect, 2020,104(3):246-251.
[12]	Liu Y, Ning Z, Chen Y, et al. Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals[J]. Nature, 2020,582(7813):557-560.
[13]	van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1[J]. N Engl J Med, 2020,382(16):1564-1567.
[14]	Rabenau HF, Cinatl J, Morgenstern B, et al. Stability and inactivation of SARS coronavirus[J]. Med Microbiol Immunol, 2005,194(1/2):1-6.
[15]	Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States[J]. N Engl J Med, 2020,382(10):929-936.
[16]	Wu YJ, Guo C, Tang LT, et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples[J]. Lancet Gastroenterol Hepatol, 2020,5(5):434-435.
[17]	National Health Commission of the People’s Republic of China. Diagnosis and treatment for COVID-19 (trial version 7), the letter of national health office and medical [2020] No. 145. [2020-03-03]. http://www.nhc.gov.cn/xcs/zhengcwj/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.(in Chinese)
	( 国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第七版), 国卫办医函〔2020〕145号.[2020-03-03]. http://www.nhc.gov.cn/xcs/zhengcwj/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml
[18]	Chinese Center for Disease Control and Prevention. Notice on the issuance of the national monitoring program for liver fluke diseases and soil-transmitted helminthiasis (Trial), China CDC [2017] No. 39. [2017-04-24].(in Chinese)
	( 中国疾病预防控制中心. 关于印发全国肝吸虫病和土源性线虫病监测方案(试行)的通知, 中疾控传防发〔2017〕39号. [2017-04-24].)
[19]	The Xinhua News Agency. In Wuhan, the detection rate of asymptomatic infections was only 0.303/10000 after the completion of centralized nucleic acid testing of nearly 9.9 milliion people[EB/OL]. (2020-6-2) [2021-6-4]. https://baijiahao.baidu.com/s?id=1668381551563218072&wfr=spider&for=pc. (in Chinese)
	( 新华社. 武汉完成近990万人集中核酸检测无症状感染者检出率仅0.303/万[EB/OL]. (2020-6-2) [2021-6-4]. https://baijiahao.baidu.com/s?id=1668381551563218072&wfr=spider&for=pc )
[20]	General Office of the National Health Commission. The control program of COVID-19. National health commission [2020] No. 204. [2020-02-18]. http://www.nhc.gov.cn/xcs/zhengcwj/202003/4856d5b0458141fa9f376853224d41d7.shtml.(in Chinese)
	( 国家卫生健康委员会办公厅. 新型冠状病毒肺炎防控方案(第六版), 国卫办疾控函﹝2020﹞204号. [2020-02-18]. http://www.nhc.gov.cn/xcs/zhengcwj/202003/4856d5b0458141fa9f376853224d41d7.shtml
[21]	Cui JJ. Reform of current disease control and prevention system based on public administration mission-orientation[J]. Adm Law Rev, 2020(5):102-116. (in Chinese)
	( 崔俊杰. 公共行政任务取向的疾病预防控制体系改革[J]. 行政法学研究, 2020(5):102-116.)
[22]	Li XH. Reshape the disease prevention and control system with the whole concept reform[J]. People’s Tribune, 2020(24):70-71. (in Chinese)
	( 李新华. 以整体观念改革重塑疾病预防控制体系[J]. 人民论坛, 2020(24):70-71.)
[23]	Wu F, Chen Y, Fu C, et al. Key issues and recommendations on restructuring China’s disease control and prevention system[J]. Chin Heal Resour, 2020,23(3):185-190, 294. (in Chinese)
	( 吴凡, 陈勇, 付晨, 等. 中国疾病预防控制体系发展改革的若干问题与对策建议[J]. 中国卫生资源, 2020,23(3):185-190, 294.)
[24]	People’s Daily Online. Overall planning, systematic remolding and all-round improvement for weaving a public health protection network[EB/OL]. (2020-5-25) [2021-6-4]. https://baijiahao.baidu.com/s?id=1667615256931822287&wfr=spider&for=pc. (in Chinese)
	( 人民网. 整体谋划系统重塑全面提升织牢织密公共卫生防护网[EB/OL]. (2020-5-25) [2021-6-4]. https://baijiahao.baidu.com/s?id=1667615256931822287&wfr=spider&for=pc. )
[25]	National Health Commission. Notice on improving infection control in fever clinics and medical institutions. Notice on improving infection control in fever clinics and medical institutions. National Health Commission [2020] No. 507. [2020-06-28]. http://www.nhc.gov.cn/yzygj/s3573d/202006/4e456696ceef482996a5bd2c3fb4c3db.shtml.(in Chinese)
	( 国家卫生健康委员会. 关于完善发热门诊和医疗机构感染防控工作的通知, [国卫办医函]507号 [2020-06-28]. http://www.nhc.gov.cn/yzygj/s3573d/202006/4e456696ceef482996a5bd2c3fb4c3db.shtml
[26]	Ahn DG, Shin HJ, Kim MH, et al. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19)[J]. J Microbiol Biotechnol, 2020,30(3):313-324.
[27]	Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR[J]. Euro Surveill, 2020,25(3):23-30.
[28]	Wang ML, Cao RY, Zhang LK, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro[J]. Cell Res, 2020,30(3):269-271.
[29]	Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies[J]. Iosci Trends, 2020,14(1):72-73.
[30]	National Institute of Parasitic Diseases, China CDC. Notice on strengthening biosafety management of biological samples of key parasitic diseases under the normal prevention and control of COVID-19, China CDC Memorandum [2020] No. 111 [2020-07-02].(in Chinese)
	( 中国疾病预防控制中心寄生虫病预防控制所. 关于新冠肺炎疫情常态化防控下加强重点寄生虫病生物样本生物安全管理工作的通知, 中疾控寄疾便函〔2020〕111号.[2020-07-02].)